Explore the latest in pharmacoeconomics, including cost-effectiveness evaluations, value-based pricing, coverage and access, and more.
This study explores the cost-effectiveness and potential budgetary consequences of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage III non–small cell lung cancer (NSCLC) in the context of the US health care system.
In this Viewpoint, the authors review Medicare & Medicaid Services 340B Payment program and recent rules to curtail expansion of drug discounts beyond serving poor patients.
This survey study examines the association of higher insulin costs with nonadherence in patients with diabetes.
This study examines the presence and extent of undeclared financial conflicts of interest among authors of clinical practice guidelines related to high-revenue medications.
This cost analysis uses National Average Drug Acquisition Cost data and US Food and Drug Administration Orange Book data to assess whether an association exists between changes in drug prices and the number of approved manufacturers for the most commonly prescribed topical dermatologic generic drugs.
This Viewpoint examines the role of benefit managers and other mechanisms driving the sustained increases in prescription drug costs in the United States.
This Viewpoint uses results of randomized clinical trials to explore whether the use of abiraterone acetate plus prednisone is a cost-effective and appropriate treatment option for patients with nonmetastatic castration-resistant prostate cancer.
This Markov model study assesses the cost-effectiveness of capecitabine and bevacizumab maintenance therapy after induction chemotherapy for treatment of metastatic colorectal cancer.
This economic evaluation assesses the cost-effectiveness of talimogene laherparepvec plus ipilimumab combination therapy vs ipilimumab monotherapy in patients with advanced unresectable melanoma from the perspective of public and private US payers.
This Viewpoint discusses a “Netflix” subscription model of drug payment being investigated by Louisiana for hepatitis C (HCV) drugs, in which a statewide coalition of payers would pay subscription fees over a fixed number of years for HCV drugs to treat all state residents and for efforts by the manufacturers to enhance treatment rates through patient outreach.
This economic evaluation uses a cost-effectiveness model with inputs including allergy fatality rates, device carriage rates, and market device costs to investigate the value-based price of an epinephrine autoinjector for children with peanut allergy.
This Viewpoint explains how group purchasing organizations (GPOs) – companies that purchase devices, supplies, and medication from multiple manufacturers and serve as single supply sources for hospitals and medical centers – contribute to supply shortages, higher prices, and limited product selection, and proposes policy solutions to overcome the adverse effects of the arrangements.
This study estimates mean 2017 total and out-of-pocket costs for infliximab and its biosimilar infliximab-dyyb under Medicare Part D.
This review discusses the problems associated with funding for development of drug therapy to treat cancer in children and proposes a financial model to address the challenges.
This retrospective analysis estimates the additional cost to Medicare of prescribing brand-name combination medications instead of generic constituents by using the Medicare data set of Part D beneficiaries prescribed any of the 1500 medications that accounted for highest total spending in 2015.
This Viewpoint uses recent case law to explore the issue of whether brand-name drug manufacturers can and should be held legally liable for medical harms from generic versions of the same drug produced by other manufacturers with identical labeling.
This systematic review and meta-analysis examines 96 studies of substandard and falsified medicines in low- and middle-income countries to determine the prevalence and estimated economic burden of these medicines.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: